Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis

The results should help the upstart drug to compete with Cosentyx.

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

The stock has already rallied 20% over the past three months, and with a new drug in the mix, it could continue to climb even higher.

Why AbbVie Could Be a Great Buy in 2020

Gaming and Leisure Properties

Owl Rock Capital Corp

OUTFRONT Media

Ready Capital Corp

Rio Tinto plc Sponsored

Tapestry

With the markets moving higher it’s harder to find high-yield stocks. Here are seven dividend stocks to consider that yield more than 5%.

7 Great High-Yield Stocks With Payouts Over 5%

Brookfield Infrastructure Partners L.P.

Innovative Industrial Properties

A big drugmaker, a global utility company, and an intriguing REIT top my list of great dividend stocks to buy.

3 High-Yield Dividend Stocks  I'd Buy Right Now

Amarin Corporation Plc

Cardinal Health

Gilead Sciences

Johnson & Johnson

Novo Nordisk

Thermo Fisher Scientific

Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.

7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount

Designer Brands

Ford Motor Company

KeyCorp

QUALCOMM

AT&T

Exxon Mobil

These seven dividend stocks come from diverse sectors of the economy, and they all offer high payouts and stock price growth.
The post 7 High-Yield Dividend Stocks Set for Growth appeared first on InvestorPlace.

7 High-Yield Dividend Stocks Set for Growth

Macy's

Written By:  Craig Adeyanju It may sound cliché but investing in dividend paying stocks is one of few ways to generate income that’s almost entirely passive. That becomes even truer for stocks in the blue-chip class.

2 High Dividend Yield Blue Chip Stocks To Buy for 2020

Shares of AbbVie Inc. ABBV, +1.25% and Allergan plc AGN, +0.83% were both up about 1% in trading on Wednesday after AbbVie announced new plans for the combined company once the pending $63 billion acquisition of Allergan closes.

AbbVie to separate Botox in new aesthetics unit; Brent Saunders won't have role

The company is leaving the aesthetics unit largely intact.

AbbVie Lays Out Plans to Integrate Allergan

Biogen

Both of these pharma giants have encountered obstacles recently, but which of them is the better buy now?

Better Buy:  AbbVie vs.  Biogen

It's another win for the company's highly priced blockbuster candidate.

AbbVie's Rheumatoid Arthritis Drug Receives Approval from Health Canada

It’s that time of the year when investment professionals provide their prognostications for 2020.

One Analyst Thinks AbbVie Is Grossly Undervalued

Sonic Automotive

Best Buy

Geopolitcal headwinds sent stocks lower on Friday as US officials confirmed that President Trump's airstrike killed Iran's top military commander.

3 Stocks with Solid Entry Points to Consider for 2020

Amgen

Anavex Life Sciences

Bristol-Myers

MannKind

Pfizer

Vertex Pharmaceuticals

Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology space.

7 Hot Drug Stocks To Buy In 2020

Hasbro

Constellation Brands

Top 3 Dividend Stocks For 2020

AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AbbVie (ABBV) Upgraded to Buy: Here's Why

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing AbbVie (ABBV) Right Now?

The stock is trading near its 52-week high even though its returns are flat this year.

Is AbbVie's Stock a Buy?

Altria

Omega Healthcare Investors

These dividend stocks yield considerable cash returns, and they will likely produce both payout and stock price increases in the 2020s.
The post 7 High-Yield Dividend Stocks for Growth and Income in the 2020s appeared first on InvestorPlace.

7 High-Yield Dividend Stocks for Growth and Income in the 2020s

Artisan Partners Asset Management

Carnival

Moelis

Ryder System

5 cheap high-yield dividend stocks with growing dividends. These five stocks have good dividend growth prospects along with high yields and low price-earnings ratios.

5 Cheap High-Yield Dividend Stocks with Growing Dividends

These are the best dividend-paying drugmakers on the market.

3 Big Pharma Stocks That Pay Big Dividends

Caterpillar

Federal Realty Investment Trust

Lowe's

The 5 Best Dividend Aristocrats To Buy For The Next Decade

Merck

The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.

3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020

Walgreens

With the S&P 500 near a record high and interest rates on the decline, high-yield dividend growth stocks are especially attractive for income investors, asserts Ben Reynolds, a contributors to MoneyShow and the editor of Sure Dividend.

The Best 4 Dividend Aristocrats For 2020

Eli Lilly

Keep in mind that short sellers betting against big pharma are taking on an added risk.

Big Pharma Short Sellers Get Selective

News for AbbVie Stock (ABBV)